Supporting Partners
The IDS & ADS gratefully acknowledges our supporting partners
Industry Partners
The IDS & ADS gratefully acknowledges the generous support of our industry partners.
Opal Partner (exclusive)
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Gold Partner
Kronus is a biotechnology company specialising in the development of high-quality diagnostic tools that support research and clinical understanding of autoimmune and metabolic diseases, including diabetes. With a strong focus on assay development and laboratory solutions, Kronus plays an important role in advancing the detection, study and monitoring of immune-related markers associated with diabetes. Through collaboration with researchers, clinicians and industry partners, Kronus contributes to improved disease characterisation and the advancement of diabetes research worldwide.
Gold Partner
SAB Biotherapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative antibody-based therapies to address complex and serious diseases, including those with immune and metabolic components such as diabetes. The company applies advanced biotechnology approaches to generate highly targeted human antibodies, supporting research and therapeutic development across diabetes and related conditions. SAB Biotherapeutics is committed to advancing new solutions that aim to improve understanding, treatment and long-term outcomes for people affected by diabetes.
Gold Partner
Enable Biosciences is a South San Francisco-based clinical laboratory and life sciences company, co-founded by a Nobel laureate, that has redefined autoantibody testing for type 1 diabetes. Its proprietary ADAP (Antibody Detection by Agglutination-PCR) platform simultaneously detects all clinically relevant T1D autoantibodies — including anti-insulin — from just 4 µL of dried blood spot sample, with best-in-class sensitivity and specificity validated in IASP proficiency workshops since 2018. Fully automated via Hamilton Robotics and interference-resistant by design, ADAP is purpose-built for population-scale screening. Today, Enable’s technology is actively deployed in partnerships across over 36 countries on four continents, establishing a new global standard for easy, early and accurate T1D detection and pre-symptomatic staging.
Red Earth Partner
Diabetes Australia is the national peak body representing people living with all types of diabetes, as well as those at risk, across the country. Working in partnership with health professionals, researchers, governments and community organisations, Diabetes Australia leads advocacy, education and awareness initiatives to improve prevention, care and support. Through evidence-based programs, policy leadership and a strong national network, Diabetes Australia plays a critical role in shaping diabetes care and driving better health outcomes for Australians.
Pearl Partner
Cytek Biosciences, Inc. is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with exquisite sensitivity. Cytek’s FSP platform includes its core instruments, the Aurora and Northern Lights™ systems, the Aurora CS cell sorter, reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers.
Pearl Partner
Lilly is a medicine company turning science into healing to make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe.
Pearl Partner
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.
Satchel Sponsor
Labcabs is a proudly owned specialist Australian courier company formed in 2002. The owner and management team have had many years of collective experience in the Life Sciences transportation industry which they have brought to the company.
Labcabs provides a flexible, speedy and reliable service for the on demand pick up and delivery of time sensitive samples and perishable products, nationwide and from almost anywhere in the world.
Over the past 23 years Labcabs has developed into one of the most trusted Australian Air courier companies and successfully operates out of all major capital cities.
Labcabs time tested agent networks are co-ordinated throughout the rest of the country to enable Labcabs to fully provide the critical edge that is demanded by all of its clients.
Poster Session Sponsors
SAB Biotherapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative antibody-based therapies to address complex and serious diseases, including those with immune and metabolic components such as diabetes. The company applies advanced biotechnology approaches to generate highly targeted human antibodies, supporting research and therapeutic development across diabetes and related conditions. SAB Biotherapeutics is committed to advancing new solutions that aim to improve understanding, treatment and long-term outcomes for people affected by diabetes.
The Australasian Type 1 Diabetes Immunotherapy Collaborative (ATIC) is a clinical trials network bringing together leading adult and paediatric endocrinologists, immunologists, researchers, trial specialists, and the type 1 diabetes community across Australia and New Zealand. ATIC’s mission is to accelerate the development and delivery of immunotherapy treatments for people living with type 1 diabetes. ATIC delivers value to industry through end‑to‑end trial support, experienced clinical trial sites, a centralised recruitment strategy, and strong community engagement. ATIC’s scientifically engaged leadership and established regulatory and clinical networks help attract global trials and shorten pathways from discovery to real‑world patient impact.